Nov. 21(Mon) 10:30-11:30 Komorebi (5F)
The Enhanced Drug Discovery Ecosystem: Leveraging AI, International Partnerships, and Innovative Funding Structures
- Organiser "session owner":
- Yoshua Bengio
- Allison Cohen, Applied AI Projects Lead, AI for Humanity – Mila
- Elliot Layne, PhD Candidate - McGill University, School of Computer Science & Mila
- Yoshua Bengio, Founder and Scientific Director, Mila – Quebec Artificial Intelligence Institute & Professor of Computer Science, University of Montreal
- Speakers and Panellists:
- Invited government officials from GPAI members and elected GPAI experts, as well as invited experts from key organisations such as the World Health Organization (WHO), AMR Action Fund, Drugs for Neglected Diseases initiative (DNDi), Global Antibiotic Research and Development Partnership (GARDP), Rapidly Emerging Antiviral Drug Development Initiative (READDI) and AI-driven Structure-enabled Antiviral Platform (ASAP). Participants to be confirmed.
The goal of this session is to outline a call to action for governments and for the broader AI and health communities to make a direct impact on critical public health challenges, including the rise of antimicrobial resistance (AMR) and the threat of future pandemics. A vision for a novel international initiative will be presented, which incorporates:
- deploying AI-enabling expertise and resources to impactful points of intervention;
- innovative funding strategies to address existing market failures;
- open data and open science methodologies.
This session targets government representatives across areas of public health, finance, innovation/science, and AI, as well as experts or industry representatives in these same domains.
The expected outcome of this session is to increase awareness of issues related to the current drug discovery ecosystem and introduce possible solutions, including increased government leadership - hopefully generating interest amongst participants to get involved.